<DOC>
	<DOC>NCT02963389</DOC>
	<brief_summary>This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients</brief_summary>
	<brief_title>A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>&gt;=6 and &lt;19yearold pediatrics with solid tumor/lymphoma Scheduled for chemotherapy requiring GCSF support or having given an experience of ANC &lt; 0.5x10^9/L ANC &gt; 0.75x10^9/L, platelet &gt; 75x10^9/L ECOG performance status 0 or 1 Patients with leukemia, myelodysplastic syndrome or uncontrolled infectious/nervous diseases History of allergy to filgrastim, pegfilgrastim or known hypersensitivity to Ecoli derived proteins. Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>